GlassScriptPhysician profile
Sharad Sathyan
NPI 1508065681
$36,591.70
in general payments reported to CMS, 2019-2025
24 companies · $35K in 2025
The $35K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $34.05 · 2021: $50.84 · 2022: $165 · 2023: $540 · 2024: $981 · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $12K · Travel and Lodging: $4,315 · Food and Beverage: $3,129 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Education: $72.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,525.00 |
| Consulting Fee | $11,625.00 |
| Travel and Lodging | $4,315.47 |
| Food and Beverage | $3,128.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Education | $72.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18,778.98 | 2019-2025 | Krystexxa, Parsabiv, Tavneos |
| Travere Therapeutics, INC. | $15,598.62 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $306.86 | 2024-2025 | |
| Novo Nordisk INC | $292.21 | 2024-2025 | Ozempic, Wegovy |
| Baxter Healthcare | $267.10 | 2019-2024 | Renal - Chronic |
| Medtronic, INC. | $228.75 | 2024-2025 | Symplicity G3, Ellipsys Vascular Access System |
| Aurinia Pharma U.S., INC. | $183.33 | 2022-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $145.06 | 2019-2025 | |
| Akebia Therapeutics INC | $136.57 | 2021-2024 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $107.61 | 2022-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $84.57 | 2023-2025 | Terlivaz |
| Horizon Therapeutics Plc | $78.87 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $57.14 | 2022-2023 | Benlysta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $56.05 | 2023-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $53.30 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $45.79 | 2020-2023 | Velphoro |
| Calliditas Therapeutics US INC. | $44.46 | 2024-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $35.58 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $34.37 | 2024-2025 | Rayaldee |
| Lilly USA, LLC | $22.18 | 2024 | Jardiance |
| Ardelyx, INC. | $19.57 | 2023 | Ibsrela |
| Shire North American Group INC | $14.73 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharad Sathyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.